Logo 1 Logo 2

Clinical Trial Details

Trial ID: L6715
Source ID: NCT01536028
Associated Drug: Biphasic Insulin Aspart 30
Title: Comparison of the Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30, 50, 70 and Insulin Aspart in Subjects With Type 1 Diabetes
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes|Diabetes Mellitus, Type 1
Interventions: DRUG: biphasic insulin aspart 30|DRUG: biphasic insulin aspart 50|DRUG: biphasic insulin aspart 70|DRUG: insulin aspart
Outcome Measures: Primary: Area under the GIR (glucose infusion rate)-curves in the first two hours post-dosing | Secondary: Maximum GIR value|Time to maximum GIR value|Area under the GIR-curves|Maximum drug concentration for insulin aspart (IAsp)|Time to maximum IAsp concentration|Area under the curve of the IAsp profiles|Minimum drug concentration in NEFA (Nonesterified fatty acids)|Time to minimum plasma concentration, NEFA|Area under the curve of the NEFA profiles|Adverse events|Hypoglycaemic episodes
Sponsor/Collaborators: Sponsor: Novo Nordisk A/S
Gender: ALL
Age: ADULT
Phases: PHASE1
Enrollment: 32
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
Start Date: 2006-04
Completion Date: 2006-07
Results First Posted:
Last Update Posted: 2017-01-06
Locations: Novo Nordisk Investigational Site, Neuss, 41460, Germany
URL: https://clinicaltrials.gov/show/NCT01536028